Analysis of virological characteristics of 2019-nCoV mutant strain concerned by WHO

doi:10.19871/j.cnki.xfcrbzz.2022.01.018

Abstract

Abstract: The outbreak of coronavirus disease 2019 poses a serious threat to human life and safety. At present, there is no clear and effective antiviral therapy for large-scale clinical use, so there are great difficulties in antiviral therapy. After the advent of the 2019-nCoV vaccine, it has shown good protective effect on the population. However, the virus is highly susceptible to mutation and the emergence of mutated strains that reduce the protection of existing vaccines against human infection and increase the risk of 2019-nCoV infection. In this paper, the virology characteristics of seven 2019-nCoV mutant strains concerned by the World Health Organization are briefly described, and the virology characteristics of seven mutant strains are summarized and analyzed, providing ideas for clinical diagnosis, treatment and drug research of this virus, with important clinical significance.

Key words: World Health Organization, Coronavirus disease 2019, Mutant, Virology characteristics analysis

Lu Hongxi, Liu Gang, Chen Xin. Analysis of virological characteristics of 2019-nCoV mutant strain concerned by WHO[J]. Electronic Journal of Emerging Infectious Diseases, 2022, 7(1): 88-91.

References

[1] LU H, STRATTON CW, TANG YW, et al.Outbreak of pneumonia of unknown etiology in Wuhan China: the mystery and the miracle[J]. J Med Virol, 2020, 92(4):401-402.
[2] 邢凯,涂晓燕,刘苗,等.COVID-19疫苗的有效性和安全性的系统评价[J].中国当代儿科杂志,2021,23(3):221-228.
[3] 靳卫平, 申硕. 新型冠状病毒肺炎疫苗临床研究进展[J]. 国际生物制品学杂志, 2021, 44(2) : 61-68.
[4] HACISULEYMAN E, HALE C, SAITO Y, et al.Vaccine Breakthrough Infections with SARS-CoV-2 Variants[J]. NEng J Med, 2021, 384(23):2212-2218.
[5] WORLD HEALTH ORGANIZATION.Tracking. SARS-CoV-2 variants[EB/OL].(2021-07-23).[2021-08-14].https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/.
[6] ALEEM A, AKBAR SAMAD AB, SLENKER AK.Emerging Variants of SARS-CoV-2 And Novel Therapeutics Against Coronavirus (COVID-19)[J].StatPearls, 2021:34033342.
[7] Nature.Coronavirus variants are spreading in India — what scientists know so far.[EB/OL].[2021-05-11].https://www.nature.com/articles/d41586-021-01274-7.
[8] CENTERS FOR DISEASE CONTROL AND PTEVENTION. SARS-CoV-2 Variant Classifications andDefinitions.[EB/OL].[2021-08-04]. https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/variant-surveillance/variant-info.html.
[9] PASCARELLA S, CICCOZZI M, ZELLA D, et al.SARS-CoV-2 B.1.617 Indian variants: Are electrostatic potential changes responsible for a higher transmission rate?[J]. J Med Virol, 2021, 93(12):6551-6556.
[10] 吴俣,刘珏,刘民,等.新型冠状病毒Omicron变异株的流行病学特征及防控研究[J].中国全科医学,2022,25(1):14-19.
[11] ARAF Y, AKTER F, TANG YD, et al.Omicron variant of SARS-CoV-2: Genomics, transmissibility, and responses to current COVID-19 vaccines[J]. J Med Virol, 2022, 94(5):1825-1832.
[12] GALLOWAY SE, PAUL P, MACCANNELL DR, et al.Emergence of SARS-CoV-2 B.1.1.7 lineage-united states, December 29, 2020-January 12, 2021[J]. MMWR Morb Mortal Wkly Rep, 2021, 70(3):95-99.
[13] GISAID R.Clade and lineage nomenclature aids in genomic epidemiology studies of active hCoV-19 viruses[EB/OL].[2021-03-02].https://www.gisaid.org/references/statements-clarifications/clade-and-lineage-nomenclature-aids-in-genomic-epidemiology-of-active-hcov-19-viruses/.
[14] FARIA NR, MELLAN TA, WHITTAKER C, et al.Genomics and epidemiology of a novel SARS-CoV-2 lineage in Manaus, Brazil[J]. medRxiv, 2021.
[15] WANG P, CASNER RG, NAIR MS, et al.Increased resistance of SARS-CoV-2 variant P.1 to antibody neutralization[J]. Cell Host Microbe, 2021, 29(5):747-751.
[16] MWENDA M, SAASA N, SINYANGE N,et al.Detection of B.1.351 SARS-CoV-2variant strain-Zambia, December 2020[J]. MMWR Morb Mortal Wkly Rep, 2021, 70(8):280-282.
[17] WIBMER CK, AYRES F, HERMANUS T, et al.SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma[J]. Nat Med, 2021, 27(4):622-625.
[18] BAJ A, NOVAZZI F, FERRANTE FD, et al.Introduction of SARS-CoV-2 C.37 (WHO VOI lambda) from Peru to Italy[J]. J Med Virol, 2021, 93(12):6460-6461.
[19] PADILLA-ROJAS C, JIMENEZ-VASQUEZ V, HURTADO V, et al.Genomic analysis reveals a rapid spread and predominance of Lambda (C.37) SARS-CoV-2 lineage in Peru despite circulation of variants of concern[J]. J Med Virol, 2021, 93(12):6845-6849.
[20] ROMERO PE, ALEJANDRA DB, GONZÁLE SL, et al.Novel sublineage within B.1.1.1 currently expanding in Peru and Chile, with a convergent deletion in the ORF1a gene(Δ3675-3677) and a novel deletion in the Spike gene
[21] XIE X, HAN JB, MA G, et al. Emerging SARS-CoV-2 B.1.621/Mu variant is prominently resistant to inactivated vaccine-elicited antibodies[J]. Zool Res, 2021, 18,42(6):789-791.
[22] LAITON-DONATO K, FRANCO-MUÑOZ C, ÁLVAREZ-DÍAZ DA, et al. Characterization of the emerging B.1.621 variant of interest of SARS-CoV-2[J]. Infect Genet Evol, 2021, 95:105038.
[23] CARLOS WG, GROSS JE, CRUZ CD, et al.Monoclonal antibodies: medical uses for the prevention and treatment of disease[J]. Am J Respir Crit Care Med, 2021, 203(11):26-27.
[24] 马亦林. 抗2019-nCoV的单克隆抗体作用机制及其制剂研究进展[J].中华临床感染病杂志, 2021, 14(2):91-96.
[25] PAN Y, DU J, LIU J, et al.Screening of potent neutralizing antibodies against SARS-CoV-2 using convalescent patients-derived phage-display libraries[J]. Cell Discov, 2021, 7(1):57.
[26] CONNOR BA, COUTO-RODRIGUEZ M, BARROWS JE, et al.Monoclonal antibody therapy in a vaccine breakthrough SARS-CoV-2hospitalized Delta (B.1.617.2) variant case[J]. Int J Infect Dis, 2021, 110:232-234.
[27] DOUGAN M, NIRULA A, AZIZAD M, et al.Bamlanivimab plus etesevimab in mild or moderate Covid-19[J]. N Engl J Med, 2021, 385(15):1382-1392.
[28] FISCHER W, ERON JJ, HOLMAN W, et al.Molnupiravir, an oral antiviral treatment for COVID-19[J]. medRxiv, 2021:34159342.
[29] 郝鹏飞, 许汪, 杜寿文, 等. 冠状病毒起源、受体及新型冠状病毒检测与疫苗最新研究进展[J/CD]. 新发传染病电子杂志, 2020, 5(2):74-78.
[30] 甘清鑫, 刘晋新, 杨彦鸿, 等. 白细胞介素-6与新型冠状病毒B.1.617.2变异株引起肺损伤相关性的人工智能定量分析[J/CD]. 新发传染病电子杂志, 2021, 6(3):172-176.